Frontiers in Oncology最新文献

{"title":"Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report.","authors":"Ilaria Gandolfini, Martina Manini, Giuseppe Daniele Benigno, Micaela Gentile, Alessandra Palmisano, Danio Somenzi, Letizia Gnetti, Marco Delsante, Benedetta Mordà, Marta D'Angelo, Daniel Salvetti, Enrico Fiaccadori, Sebastiano Buti, Umberto Maggiore","doi":"10.3389/fonc.2025.1506324","DOIUrl":"https://doi.org/10.3389/fonc.2025.1506324","url":null,"abstract":"<p><p>We report on the first case of a dual-kidney transplant recipient diagnosed with a metastatic BK polyomavirus-positive clear renal cell carcinoma with sarcomatoid features, which caused extensive vena cava thrombosis. The patient was successfully treated with the immune checkpoint inhibitors (ICIs) ipilimumab plus nivolumab and continued immunosuppression with tacrolimus, mycophenolate, and steroids. He received ICIs despite the presence of graft dysfunction due to transplant glomerulopathy. As expected, the ICI treatment caused a progressive but asymptomatic decline of the graft function, which resulted in end-stage kidney disease. However, continuation of a full immunosuppression prevented acute rejection, graft intolerance syndrome episodes, or dual graft nephrectomy, which enabled the patient to successfully continue ICIs while on dialysis and to achieve sustained partial remission at the 17-month follow-up.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1506324"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: a systematic review.","authors":"Sara Dall' Armellina, Gayane Aghakhanyan, Alessio Rizzo, Salvatore C Fanni, Giacomo Aringhieri, Lorenzo Faggioni, Dania Cioni, Emanuele Neri, Duccio Volterrani, Silvia Morbelli","doi":"10.3389/fonc.2025.1553505","DOIUrl":"https://doi.org/10.3389/fonc.2025.1553505","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate-Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein initially identified in prostate cancer (PCa) but also expressed in the neovasculature of various solid tumors. Recently, PSMA PET has emerged as a promising tool for detecting brain metastases (BMs) from non-prostatic cancers, offering diagnostic capabilities in addition to conventional imaging. This systematic review evaluates the role of PSMA-targeted radiopharmaceuticals in imaging BMs, highlighting their comparative diagnostic performance and exploring their potential for theranostic applications.</p><p><strong>Methods: </strong>A systematic review of the literature was conducted following PRISMA guidelines. Studies evaluating the diagnostic accuracy of PSMA PET imaging in identifying brain metastases (BMs) from non-prostatic solid tumors were included. Both full research articles and case reports were considered to capture the breadth of current evidence. The methodological quality of the included studies was assessed using the QUADAS-2 tool, and data were synthesized qualitatively.</p><p><strong>Results: </strong>The review includes 23 studies reporting on 77 BMs from diverse primary malignancies, including lung, breast, salivary gland, thyroid, kidney, and melanoma. PSMA PET demonstrated high tumor-to-background ratios (TBR), enabling superior detection of BMs compared to conventional imaging modalities such as contrast-enhanced MRI and [18F]FDG PET. In post-radiotherapy cases, PSMA PET effectively differentiated radionecrosis from tumor recurrence. Moreover, PSMA PET demonstrated superior sensitivity in detecting thyroid metastases compared to traditional scintigraphy methods, highlighting its potential in cases where standard techniques yield inconclusive results.</p><p><strong>Conclusions: </strong>PSMA PET imaging shows significant promise in improving the diagnosis and management of BMs from non-prostatic cancers. While its theranostic applications remain underexplored, initial findings suggest promising avenues for integrating PSMA PET into personalized neuro-oncology care. Future studies should focus on standardizing imaging protocols, exploring PSMA PET utility in diverse tumor subtypes, and validating its role in clinical decision-making to maximize its impact on patient outcomes.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1553505"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour habitat-based radiomics analysis enhances the ability to predict prostate cancer aggressiveness with biparametric MRI-derived features.","authors":"Mengjuan Li, Ning Ding, Shengnan Yin, Yan Lu, Yiding Ji, Long Jin","doi":"10.3389/fonc.2025.1504132","DOIUrl":"https://doi.org/10.3389/fonc.2025.1504132","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to develop three predictive models utilising clinical factors, radiomics features, and habitat features, to distinguish between nonclinically significant prostate cancer (csPCa) and clinically significant PCa (non-csPCa) on the basis of biparametric MRI (bp-MRI).</p><p><strong>Methods: </strong>A total of 175 patients were enrolled, including 134 individuals with csPCa and 41 with non-csPCa. The clinical model was developed using optimal predictive factors obtained from univariable logistic regression and modelled through a random forest approach. Image acquisition and segmentation were performed first in the creation of both the radiomics model and the habitat model. The K-means clustering algorithm was then used exclusively for habitat generation in the development of the habitat model. Finally, feature selection and model construction were performed for both models. Model comparison and diagnostic efficacy assessment were conducted through receiver operating characteristic curve analysis, decision curve analysis (DCA), and calibration curve analysis.</p><p><strong>Results: </strong>The habitat model outperformed both the radiomics model and the clinical model in distinguishing csPCa from non-csPCa patients. The AUC values of the habitat model in the training and test sets were 0.99 and 0.93, respectively. Furthermore, DCA and the calibration curves highlighted the superior clinical utility and greater predictive accuracy of the habitat model in comparison with the other two models.</p><p><strong>Conclusion: </strong>We developed a habitat-based radiomics model with a greater ability to distinguish between csPCa and non-csPCa on the basis of bp-MRI than a traditional radiomics model and clinical model. This introduces a novel approach for assessing the heterogeneity of PCa and offers urologists a quantitative, noninvasive method for preoperatively evaluating the aggressiveness of PCa.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1504132"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case Report: an extremely rare case of giant dedifferentiated retroperitoneal liposarcoma.","authors":"Huey Bing Chua, Rizuana Iqbal Hussain, Nordashima Abd Shukor, Xeng Inn Fam","doi":"10.3389/fonc.2025.1489833","DOIUrl":"https://doi.org/10.3389/fonc.2025.1489833","url":null,"abstract":"<p><p>Retroperitoneal liposarcoma, especially dedifferentiated liposarcoma (DDL), is a rare tumor type primarily affecting middle-aged and older adults in the retroperitoneum or proximal extremities. This case report highlights an exceptionally large retroperitoneal DDL that had enveloped the entire right kidney and had adhered to nearby tissues. Diagnosing retroperitoneal liposarcoma is challenging due to its asymptomatic nature until it reaches a substantial size. Imaging, particularly contrast-enhanced computed tomography (CECT), play a vital role in diagnosis, staging, and preoperative planning. Surgical resection, with the goal of R0 resection, remains the cornerstone of treatment, albeit this can be challenging due to tumor location. First-line treatment for advanced DDL involves anthracycline-based therapy. Eribulin and pazopanib show promise in second-line treatment. Ongoing clinical trials suggest a shift towards multimodal therapy. This case report reports the largest retroperitoneal liposarcoma and underscores the complexity of managing retroperitoneal DDL.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1489833"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioinformatics and experimental approach reveal potential prognostic and immunological roles of key mitochondrial metabolism-related genes in cervical cancer.","authors":"Qing Huang, Yang-Feng Xu, Hui-Ping Li, Ting Zhang","doi":"10.3389/fonc.2025.1522910","DOIUrl":"https://doi.org/10.3389/fonc.2025.1522910","url":null,"abstract":"<p><strong>Background: </strong>Metabolic remodeling is the hallmark of cancer. In recent years, mitochondrial metabolism (MM) has been considered essential in tumorigenesis and cancer progression. Understanding the role of MM in cervical cancer (CC) can provide insights into disease progression and potential therapeutic targets.</p><p><strong>Methods: </strong>Clinical data of CC patients was downloaded from the UCSC Xena dataset, and differentially expressed genes (DEGs) were identified between tumor and normal samples. MM-related genes (MMRGs) were screened from the MSigDB database. DEGs and MMRGs were then intersected to identify differentially expressed MMRGs. A prognostic risk model was constructed based on these intersecting genes through Cox regression analysis, and its association with the tumor microenvironment and immune checkpoint-related genes was evaluated. Hub genes' expression was evaluated in cells through qRT-PCR. Additionally, drug sensitivity analysis was conducted to explore potential therapeutic drugs.</p><p><strong>Results: </strong>We identified 259 overlapping genes between DEGs and MMRGs, with 55 being prognosis-related. Two molecular clusters were revealed, with C1 exhibiting poorer prognosis. A prognostic risk model comprising five genes (BDH1, MIR210, MSMO1, POLA1, and STARD3NL) was established, showing significant associations with survival outcomes of CC patients. Functional enrichment analysis revealed that DEGs between high- and low-risk groups were tightly associated with the immune system. Analysis of the immune microenvironment showed significant differences between different risk groups, with higher immune and ESTIMATE scores observed in the low-risk group. Additionally, expression levels of immune checkpoint-related genes were significantly correlated with the risk score. Drug sensitivity analysis identified potential therapeutic agents correlated with the expression of the five prognostic genes.</p><p><strong>Conclusion: </strong>Our findings underscore the importance of MM in CC progression and provide potential therapeutic targets for CC.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1522910"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade.","authors":"Yoshiya Ohno, Haruki Okamura, Hideo Yagita, Toshiyuki Tanaka","doi":"10.3389/fonc.2025.1533808","DOIUrl":"https://doi.org/10.3389/fonc.2025.1533808","url":null,"abstract":"<p><p>The success of cancer immunotherapy depends on the effective coordination of innate and adaptive immunity. We previously reported that IL-18 potentiates the therapeutic effects of immune checkpoint inhibitors in mouse models. Here, we report that IL-18-primed natural killer (NK) cells enhanced the antitumor effects of anti-PD-1 antibodies by mobilizing type 1 conventional dendritic cells (cDC1s) to tumor sites and promoting type 1 immune responses. IL-18-primed NK cells had a premature phenotype, and expressed chemokines involved in cDC1 mobilization. In a combination treatment with IL-18 and anti-PD-1 antibody, NK cell depletion inhibited cDC1 mobilization and abrogated the therapeutic effects. Additionally, adoptive transfer of IL-18-primed NK cells induced cDC1 mobilization and enhanced the therapeutic effects of anti-PD-1 antibodies. IL-18 also increased IL-12 mRNA expression in DCs and IL-12 blood levels, and IL-12 upregulated XCL1 expression in NK cells. These results suggest that IL-18 primes NK cells and enhances the therapeutic effects of immune checkpoint inhibitors by promoting a feed-forward loop involving DCs.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1533808"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How effective is acupuncture in treating hot flashes in breast cancer patients? A systematic review and meta-analysis.","authors":"Genlan Zhang, Cui Gao, Zining Guo, Wenrui Zhao, Xufang Xu, Huaneng Wen, Yaoxuan Li, Run Lin, Nenggui Xu, Shaoyang Cui","doi":"10.3389/fonc.2025.1543938","DOIUrl":"https://doi.org/10.3389/fonc.2025.1543938","url":null,"abstract":"<p><strong>Background: </strong>Although acupuncture is recommended for managing breast cancer-related hot flashes, the level of evidence is limited. With the updating of randomized controlled trials, it is necessary to reassess its efficacy.</p><p><strong>Objective: </strong>To assess the effectiveness of acupuncture in the treatment of hot flashes in patients with breast cancer.</p><p><strong>Methods: </strong>Up to March 2024, we retrieved data from nine databases and used Stata software (version 14.0, version 17.0) and RevMan software (version 5.3) to conduct a meta-analysis. The Cochrane Collaboration's risk of bias assessment tool was used for methodological assessment of the risk of bias, and the GRADEpro GDT online assessment tool was used for evidence evaluation.</p><p><strong>Results: </strong>In total, 11 randomized controlled trials (RCTs) involved 963 participants were included in the meta-analysis. The result of risk of bias revealed that the included RCTs exhibited a high risk of bias, primarily attributable to deficiencies in randomization and blinding methods. The results of primary meta-analysis indicated that acupuncture can improved the hot flash symptom scale score (SMD, -0.54; 95% CI, -0.83 to -0.24; <i>P <</i> 0.05). However, acupuncture does not reduce the frequency of hot flashes(SMD, -0.20; 95% CI, -0.75 to 0.36; <i>P = 0.48</i>). Further subgroup analyses, including the type of control group and the duration of needle retention, etc. showed different results, highlighting the necessity for further research. Sensitivity analysis confirmed the reliability of these finding. In addition, due to various issues, the level of evidence is low.</p><p><strong>Conclusions: </strong>Although acupuncture treatment for hot flashes in breast cancer shows potential, the evidence for the efficacy of acupuncture is still lacking due to various factors such as bias risk and significant differences between studies, and more high-quality RCTs are needed to confirm the efficacy of acupuncture.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/, identifier CRD42024531542.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1543938"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-surgical organ preservation and new technologies in laryngeal radiation.","authors":"Dietz Andreas, Eckel Hans, Alexander deVries, Markus Brunner","doi":"10.3389/fonc.2024.1494854","DOIUrl":"https://doi.org/10.3389/fonc.2024.1494854","url":null,"abstract":"<p><p>The term \"larynx organ preservation\" (LOP) has become a synonym for non-surgical laryngeal cancer treatment based on chemotherapy and radiation multimodality therapy [simultaneous chemoradiation (CRT) or neoadjuvant chemotherapy followed by radiotherapy (NCT+RT)]. Currently, the distinction between good and bad candidates for LOP is not clear, and the decision for surgical or non-surgical treatment depends on the patient's needs and desires, the experience and recommendation of the surgeon, the philosophy of the institution, and others. Nevertheless, the major disadvantage of LOP by CRT and NCT+RT is the potential need for salvage surgery due to tumor persistence after the application of full per-protocol treatment. Head and neck surgeons worldwide complain that in principle, salvage surgery is frequently possible after CRT but causes major complications and is not feasible in a relevant number of patients. While NCT+RT is globally used to select responders for LOP, NCT alone has not been shown to improve overall survival. Therefore, this procedure has lost its influence in standard head and neck cancer treatment beyond LOP. Recently, NCT as part of the perioperative transoral surgical treatment concept in head and neck cancer is gaining interest again. In addition to conventional chemotherapy, the combination with immune checkpoint inhibitors as a neoadjuvant concept has shown to be effective in non-controlled trials by opening a new door of encouraging treatment options for LOP.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"14 ","pages":"1494854"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary prostatic Burkitt's lymphoma complicated with hemophagocytic lymphohistiocytosis: a case report and literature review.","authors":"Xiong Guo, Wei Ai, Zhi Zhang, Zonglai Liu, Haibo Fu, Pan Gao, Fajun Liu","doi":"10.3389/fonc.2025.1553415","DOIUrl":"https://doi.org/10.3389/fonc.2025.1553415","url":null,"abstract":"<p><p>This article reports a very rare case of primary prostatic Burkitt's lymphoma. After transurethral resection of the prostate, the patient developed hemophagocytic lymphohistiocytosis, which rapidly progressed, leading to the patient's death. Unfortunately, a definitive diagnosis was made only in the advanced stages of the disease, contributing to a delay in diagnosis and worsening of the patient's condition. This report aims to improve the understanding of this disease and aid in its early recognition.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1553415"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The influence of the microbiome on radiotherapy and DNA damage responses.","authors":"Aadil Sheikh, Michael A Curran","doi":"10.3389/fonc.2025.1552750","DOIUrl":"https://doi.org/10.3389/fonc.2025.1552750","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is one of the most prevalent cancers in terms of diagnosis and mortality. Radiotherapy (RT) remains a mainstay of CRC therapy. As RT relies on DNA damage to promote tumor cell death, the activity of cellular DNA damage repair pathways can modulate cancer sensitivity to therapy. The gut microbiome has been shown to influence intestinal health and is independently associated with CRC development, treatment responses and outcomes. The microbiome can also modulate responses to CRC RT through various mechanisms such as community structure, toxins and metabolites. In this review we explore the use of RT in the treatment of CRC and the molecular factors that influence treatment outcomes. We also discuss how the microbiome can promote radiosensitivity versus radioprotection to modulate RT outcomes in CRC. Understanding the molecular interaction between the microbiome and DNA repair pathways can assist with predicting responses to RT. Once described, these connections between the microbiome and RT response can also be used to identify actionable targets for therapeutic development.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1552750"},"PeriodicalIF":3.5,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}